G&G Biotechnology Launches New Branding for B-Lite – the World’s First and Only Lightweight Breast Implant Set to Transform Breast Aesthetics. Forever.

AMSTERDAM, June 1, 2017 /PRNewswire/ —

New strategic branding to be presented at the Beauty Through Science Conference, Stockholm, Sweden, June 1-3.

G&G Biotechnology BV., announced today at the Beauty Through Science Conference, Stockholm, Sweden, the launch of its new strategic branding for the innovative B-Lite® Lightweight Breast Implants. These groundbreaking implants are the world’s first & only lightweight breast implants and are set to transform breast aesthetics forever for both physicians and patients.

     (Logo: http://mma.prnewswire.com/media/517160/B_Lite_Logo.jpg )
     (Photo: http://mma.prnewswire.com/media/517161/B_Lite.jpg )

Mr. Dael Govreen-Segal, the company CEO, stated: „The new strategic branding reflects the company’s commitment to meaningful innovation in the breast aesthetics field.” Mr Govreen-Segal also added that „the new branding already received tremendous positive feedback from both customers and the media.”

B-Lite’s prominent presence at the BTS scientific program includes lectures on „The effect of microsphere enhanced silicone gel on gel bleed and radiolucency” by Prof. Michael Scheflan, MD, and „Large interest for lightweight breast implants by patients – experiences from my first 100 cases” by Nikolaus Raab, MD.

The company will also host its annual Scientific Advisory Board meeting prior to the BTS to discuss the B-Lite product roadmap and strategic directions.

About B-Lite

Up to 30% lighter than traditional implants, B-Lite implants are designed to reduce gravitational stress on the breast soft-tissue. Adapted from advanced technologies used by NASA, B-Lite’s proprietary microsphere-enhanced silicone implants are built to retain the breast shape and form, while offering top grade safety and aesthetic outcome.

Implanted using standard surgical procedures, B-Lite allows plastic surgeons to confidently leverage their expertise with no additional training needed. Rigorous clinical follow up of the CE-marked device, demonstrate excellent clinical experience, very high patient satisfaction and an excellent safety profile.

„For patients and surgeons, it is very intuitive to reduce the weight of breast implants” stated Kai-Uwe Schlaudraff, MD, Geneva, Switzerland „My patients love the comfort of B-Lite implants and I firmly believe B-Lite will become the new standard in next-generation breast augmentation.”

About G&G Biotechnology 

Founded in 2005, G&G Biotechnology, backed by Sequoia Capital, is transforming the breast augmentation and reconstruction industry with B-Lite, the world’s first and only lightweight breast implant.

B-Lite’s premium offer and the company’s unwavering commitment to meaningful innovation, safety and quality gives confidence to both surgeons and patients, delivering outstanding satisfaction and sustainable long-term benefits.

For additional information: info@b-lite.com or visit http://www.b-lite.com

SOURCE G&G Biotechnology BV

Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome

MADRID, June 1, 2017 /PRNewswire/ —

The pharmaceutical Company Sylentis (PharmaMar Group) has announced the start of the first Phase III study, HELIX, with the investigational new drug, SYL1001 for the indication of dry eye syndrome. The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA). The Company has received final, End-of-Phase II meeting minutes from the FDA.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

SYL1001 is an advance in the development of innovative compounds in different therapeutic fields, through the novel technology of gene silencing, based on RNA interference (RNAi). In the HELIX study, more than 30 centers from 5 European countries (Spain, Germany, Estonia, Portugal and Italy) will participate with the objective of evaluating the effect of the ophthalmological solution SYL1001 for improvements in the signs and symptoms of dry eye syndrome in about 300 patients an area in which few therapeutic options exist today. SYL1001 is a compound based on RNAi being administered in the form of eye drops that block the synthesis of a receptor implicated in the pathology of dry eye syndrome.  

Patients with dry-eye syndrome suffer the chronic loss of lubrication and hydration on the ocular surface. The risk of developing this disorder increases in 35% every decade thereafter[2]. Around the world, 344 million people suffer from this syndrome.

Dry eye syndrome is characteristic in people that live in developed countries and is caused by pollution, air conditioning, the use of contact lenses, refractive eye surgery or the continued use of computers. The most common symptoms of this pathology are burning, a constant itching, eye fatigue, dryness, blurred vision, the sensation of having a foreign body or eye pain[1], are some of the symptoms

As explained by Dr Ana Isabel Jimenez, COO and Director of R&D at Sylentis, the RNA interference on which we are working, could improve the signs and symptoms for patients that suffer from this syndrome, given that this compound could reduce the inflammatory parameters of the eye´s surface, could improve the quality of the tear and could reduce the ocular pain associated with dry eye syndrome. We consider that our molecule SYL1001 could be a very effective and important therapeutic alternative for these patients.

The Company is working on the investigation of new treatments for ophthalmological and inflammatory illnesses. Up to today, the line of work in which we have more rapidly advanced in is in ophthalmology, for the treatment of illnesses such as dry eye syndrome, glaucoma, ocular allergies and illnesses of the retina, added Dr Jimenez.  

What is RNA interference? 

RNA interference is an innovative technology that looks for a reduction in the anomalous production of protein, silencing the RNA Messenger. The RNAi provides a step forward, as it provides a new mechanism of action to confront numerous pathologies[2]. Nowadays there are two marketed products based on this technology and there are several drugs in different phases of clinical development.

Pathologies, such as dry eye syndrome, are produced by an alteration in certain proteins. Through this technology, the production of proteins that take part in various pathologies could be decreased or very specifically controlled[3].

HELIX, a clinical trial study 

With the purpose of progressing in this field, Sylentis has begun the multicenter, random, controlled and double blind Phase III clinical trial in more than 30 hospitals in Spain, Germany, Estonia, Portugal and Italy. The trial, in which 300 patients are going to be enrolled will evaluate the efficacy of the product patented by Sylentis, SYL1001, in the treatment of the signs and symptoms of dry eye disease[4].

For more information about the clinical trial: https://clinicaltrials.gov/ct2/show/NCT03108664?term=SYL1001&rank=2

For more information (only available in Spanish) 

Whats is RNA interference? https://youtu.be/T21N_dPM0_k

Dry eye syndrome: https://youtu.be/R-h_4_Yyq2g

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf, 2007. 5(2): p. 75-92 

2. Martínez T, Jimenez AI, Pañeda C. Short-interference RNAs: becoming medicines. EXCLI Journal, 2015;14:714-46 

3. Pañeda C, González V, Martínez T, Ruz V, Vargas B and Jimenez AI. RNAi based therapies for ocular conditions. In Proceedings of the 11th ISOPT,2014, 25-30, Medimond, Bologna, Italy 

4. Benitez-Del Castillo JM [https://www.ncbi.nlm.nih.gov/pubmed/?term=Benitez-Del-Castillo%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=27893109 ], . Protocol No.: SYL1001_IV. EUDRACT No: 2016-003903-79. A double-masked study of SYL1001 in patients with moderate to severe dry eye disease (DED). HELIX Study (Phase III). Version 1.1: December 14th, 2016. Sylentis SAU-Pharma Mar Group 

CONTACTS : Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)

SOURCE PharmaMar

Faraday Announces the World’s First Automotive ASIC Qualified for AEC-Q100 and AEC-Q006

HSINCHU, Taiwan, June 1, 2017 /PRNewswire/ — Faraday Technology Corporation (TWSE: 3035), a leading ASIC design service and IP provider, announced today that it has completed the first-ever automotive ASIC device qualified for AEC-Q100 and AEC-Q006 as defined by the Automotive Electronics Council (AEC). This milestone achievement demonstrates Faraday’s readiness to participate in this quality-driven marketplace bringing considerable ASIC/SoC design and manufacturing capability to automotive applications.

This AEC-qualified ASIC device on UMC 40nm was co-developed with a World-Class automotive IC provider. It is packaged in a standard 324BGA with copper bond wiring for maximum cost effectiveness. During the development phase, Faraday played a key role in managing and coordinating all constituent suppliers to ensure conformity to all corresponding reliability methods and standards. In addition to guaranteeing the outgoing quality of the shipped devices, Faraday also provided all of the testing methodology and circuits, with strict test patterns based on typical automotive operating environments. The first silicon sample out of UMC Fab was successfully verified in system and passed all AEC-Q100/Q006 reliability testing.

„In addition to becoming the first ASIC Design Services firm approved to ISO 26262 in 2016, Faraday has now successfully produced our first ASIC chip qualified for AEC-Q100 and AEC-Q006,” said Steve Wang, President of Faraday. „To meet the rapidly rising demand from the automotive market, Faraday has built up related know-how and technology for providing a trusted automotive ASIC solution with optimized quality, reliability and cost,” he added.

About Faraday Technology Corporation

Faraday Technology Corporation is a leading fabless ASIC and silicon IP provider, certificated to ISO 9001 and ISO 26262. The broad silicon IP portfolio includes I/O, Cell Library, Memory Compiler, ARM-compliant CPUs, DDR2/3/4, low-power DDR1/2/3, MIPI, V-by-One, MPEG4, H.264, USB 2.0/3.1 Gen 1, 10/100/1000 Ethernet, Serial ATA, PCI Express, and programmable SerDes, etc. Headquartered in Taiwan, Faraday has service and support offices around the world, including the U.S., Japan, Europe, and China. Faraday is listed on the Taiwan Stock Exchange, ticker 3035. For more information, please visit www.faraday-tech.com.

SOURCE Faraday Technology Corporation

Related Links


Exercise of Warrants and Options



Faron Pharmaceuticals Oy

(„Faron” or the „Company”)


Exercise of Warrants and Options

Issue of Equity


TURKU – FINLAND, 1 June 2017 – Faron Pharmaceuticals Ltd („Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that it has received a notification from a warrant holder to exercise warrants over 71,370 ordinary shares in the Company at an exercise price of €1.55 per share and a further 27,040 ordinary shares in the Company at an exercise price of €2.01 per share providing the Company with gross proceeds of €164,973.90 (approximately £143,082).


The Company further announces that it has received a notification from an option holder to exercise options over 15,000 ordinary shares in the Company at an exercise price of €3.71 per share and a further 14,100 ordinary shares in the Company at an exercise price of €2.90 per share providing the Company with gross proceeds of €96,540.00 (approximately £83,729).


Application will be made to the London Stock Exchange to admit the 127,510 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 06 June 2017 („Admission”).  The new ordinary shares will rank pari passu with existing ordinary shares. Issue of the new ordinary shares remains subject to such shares being registered at the Finnish Trade Registry.


Faron’s enlarged issued number of shares immediately following registration and Admission will be 27,914,544 ordinary shares with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, registration, the total number of voting rights in Faron will be 27,914,544. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the issued shares and votes of the Company.


For more information please contact:


Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer



Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com


Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com


Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson

Phone: +44 207 213 0880


Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500


Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234


About Faron Pharmaceuticals Ltd


Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, cancer immunotherapy and vascular damage. The pipeline is built on Faron’s scientific knowledge and control of the endothelial barrier, the membrane of cells lining blood and lymphatic vessels to separate blood content from tissues. The Company’s lead candidate Traumakine® is in development for the treatment of Acute Respiratory Distress Syndrome („ARDS”), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine is currently in pan-European (INTEREST) and Japanese pivotal Phase III studies. Additionally, Faron is developing Clevegen® a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to convert the immune environment around a tumour from being immune suppressive to immune stimulating. This novel macrophage-directed immuno-oncology approach is called Tumour Immunity Enabling Technology („TIET”) and can be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. New application opportunities related to TIET cover chronic infections and inefficient vaccination. Based in Turku, Finland, Faron Pharmaceuticals is listed on AIM under the ticker ‚FARN’. Further information is available at www.faronpharmaceuticals.com




North America Plastisol Ink industry Outlook 2022: key players, Analysis by Applications and growth Prediction

North America Plastisol Ink Market analysis is provided for global market including development trends by regions, competitive analysis of the North America Plastisol Ink market. North America Plastisol Ink Industry report focuses on the major drivers and restraints for the key players. Plastisol ink is a PVC-based industrial coating for screen printing cotton, polyester, nylon etc. New generation of products appeared in the market in recent years: non-phthalate plastisol inks and non-pvc plastisol inks. This North America Plastisol Ink market report of 120 Pages speaks about the manufacturing process analysed thoroughly with respect four points Manufacturers, regional analysis, Segment by Type and Segment by Applications and the actual process of whole North America Plastisol Ink industry.

Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in North America Plastisol Ink Market Research Report @ http://www.marketreportsworld.com/10376340

Market Segment by Manufacturers includes PolyOne, Lancer Group, Rutland Plastic Technologies, ICC, Huber Group, Fujifilm, Sunlan Chemicals, KARAN, Zhongyi Ink & Paint, Sophah Screen Printing Technology, Dexin. And many more. Market Segment by Type includes General Plastisol Inks, Non-Phthalate Plastisol Inks, Non-PVC Plastisol Inks.  Market Segment by Applications includes Cotton Fabric, Polyester & Nylon Fabrics, Blend Fabric, Others.

Get Sample PDF of North America Plastisol Ink Market Report at- http://www.marketreportsworld.com/enquiry/request-sample/10376340

Scope of the Report: This report focuses on the North America Plastisol Ink in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Highlights of Global North America Plastisol Ink Market Research Report: To show the North America Plastisol Ink market by type and application, with sales market share and growth rate by type, application. North America Plastisol Ink market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021. Describe North America Plastisol Ink Market Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Analyse the top manufacturers of North America Plastisol Ink Industry, with sales, revenue, and price. Display the competitive situation among the top manufacturers, with sales, revenue and market share of North America Plastisol Ink Market. To show the global market by regions, with sales, revenue and market share of North America Plastisol Ink Industry, for each region. Analyse the key regions, with sales, revenue and market share by key countries in these regions. Describe North America Plastisol Ink Industry sales channel, distributors, traders, dealers, appendix and data source.

Get Full Report at $ 4480 (Single User License) at http://www.marketreportsworld.com/purchase/10376340



G&G Biotechnology startet ein neues Branding für B-Lite, das weltweit erste und einzige Brustimplantat mit geringem Gewicht, das die ästhetische Brustchirurgie verändern wird. Für immer.

AMSTERDAM, June 1, 2017 /PRNewswire/ —

Auf der vom 1. bis zum 3. Juni in Stockholm, Schweden, veranstalteten Beauty Through Science Conference wird ein neues strategisches Branding präsentiert.  

G&G Biotechnology BV., gaben heute auf der in Stockholm, Schweden, stattfindenden Beauty Through Science Conference den Start des neuen strategischen Brandings für die innovativen B-Lite®-Brustimplantate mit geringem Gewicht bekannt. Diese revolutionären Implantate sind die weltweit ersten und einzigen Brustimplantate mit geringem Gewicht und verändern auf Dauer die ästhetische Brustchirurgie für Ärzte und Patientinnen.

     (Logo: http://mma.prnewswire.com/media/517160/B_Lite_Logo.jpg )
     (Photo: http://mma.prnewswire.com/media/517161/B_Lite.jpg )

Dael Govreen-Segal, der CEO des Unternehmens, sagte: „Das neue strategische Branding ist ein Zeichen für das Engagement des Unternehmens zu einer sinnvollen Innovation im Bereich der ästhetischen Brustchirurgie.” Er sagte ebenfalls, dass „das neue Branding von Ärzten, Patientinnen und den Medien äußerst positiv aufgenommen wurde”.

Die ausgeprägte Präsenz von B-Lite auf dem wissenschaftlichen Programm des BTS ist gekennzeichnet durch Vorträge über „den Effekt einer Kombination aus Mikrokügelchen und Silikongel, auf das verminderte Risiko des Austreten von Gel und auf eine verbesserte (Mammographie-) /(Radiologie-) Fähigkeit” von Prof. Dr. Michael Scheflan und das „große Interesse der Patientinnen an leichten Brustimplantaten − Erfahrungen aus den ersten 100 Fällen” von Dr. Nikolaus Raab.

Das Unternehmen hält außerdem die jährliche Sitzung des wissenschaftlichen Beirats vor dem BTS ab, um den Fahrplan und die strategische Ausrichtung von B-Lite zu diskutieren.

Informationen zu B-Lite  

B-Lite-Implantate sind bis zu 30 % leichter als herkömmliche Implantate und verringern die Belastung des weichen Brustgewebes durch die Schwerkraft. Die in Anlehnung an moderne Technologien der NASA entwickelten, durch Mikrokügelchen stabilisierten Silikonimplantate erhalten die Form der Brust, bieten ein hohes Maß an Sicherheit und sorgen für Formschönheit der Brust.

B-Lite wird mit einer Standardoperation implantiert. Dies ermöglicht Plastischen Chirurgen, ihr Wissen zu nutzen, ohne sich weiteren Schulungen unterziehen zu müssen. Strenge klinische Überwachungen des mit dem CE-Kennzeichen versehenen Implantats ergaben ausgezeichnete Erfahrungen der Ärzte, hohe Zufriedenheit bei den Patientinnen und ein hervorragendes Sicherheitsprofil.

„Für Patientinnen und Chirurgen liegt es nahe, das Gewicht der Brustimplantate zu reduzieren”, sagte Dr. Kai-Uwe Schlaudraff, Genf, Schweiz. „Meine Patientinnen sind von dem Komfort der B-Lite-Implantate begeistert und ich bin fest davon überzeugt, dass B-Lite der neue Standard für künftige Brustvergrößerungen sein wird.”

Informationen zu G&G Biotechnology  

G&G Biotechnology wurde 2005 gegründet und revolutioniert mit finanzieller Unterstützung von Sequoia Capital die Brustvergrößerung und -Rekonstruktion mit B-Lite, dem weltweit ersten und einzigen Brustimplantat mit geringem Gewicht.

Das Flaggschiffprodukt B-Lite und das kontinuierliche Engagement des Unternehmens für sinnvolle Innovation, Sicherheit und Qualität gibt Chirurgen und Patienten Vertrauen, ein hohes Maß an Zufriedenheit und langfristige Vorteile.

Weitere Informationen erhalten Sie unter info@b-lite.com oder auf http://www.b-lite.com

SOURCE G&G Biotechnology BV

Completion of the Baverstock Merger

Caspian Sunrise Plc


Caspian Sunrise plc („Caspian Sunrise” or the „Company”)


Completion of the Baverstock Merger





Caspian Sunrise, the Central Asian oil and gas company, with a focus on Kazakhstan, is pleased to announce the completion of the merger with Baverstock GmbH, („Baverstock”).


The final condition of the merger was satisfied this morning being the admittance to trading on AIM of the 651,436,544 merger shares („Baverstock Merger”) shares.


Additionally the company is pleased to announce the completion of the capitalisation of some $10.1 million of the Vertom loan. Vertom is a company controlled by the Company’s CEO Kuat Oraziman.


Accordingly, under the terms of the Merger Agreement, Caspian Sunrise has issued 651,436,544 new Ordinary Shares to Baverstock. Additionally, a further 80,804,200 Conversion Shares have been issued to Vertom pursuant to the Conversion of Vertom Loan.


Benefits of the Merger


The Caspian Sunrise Group now holds a 99% interest in its principal asset, BNG, which the Caspian Sunrise Board firmly believes should become an extremely valuable asset and 99% interests in its other active asset Munaily.


Previously the funding of the development of BNG was the joint responsibility of Caspian Sunrise and Baverstock on a 59; 41 basis. Following the completion of the Baverstock Merger, Caspian Sunrise can now alone set the pace at which the BNG asset will be exploited.


Other benefits include becoming a materially larger company and the removal of any perceived conflicts of interest connected with the Company’s CEO Kuat Oraziman, who is the largest shareholder in Baverstock.


Additionally, with 99% of the operating assets under the direct control of Caspian Sunrise Group it will be possible to simplify the Group structure and better manage the Group’s taxation affairs.


Benefits of the Debt conversion


The Company is, except for local oil trader short term funding, essentially debt free 


Baverstock’s shareholding


Following the completion of the Baverstock Merger and the Vertom debt conversion Baverstock holds 749,436,544 Caspian Sunrise shares representing 44.89% of the enlarged total.


The effective split within Baverstock among the 4 Quota-holders is:


Kuat Oraziman                                   54.24%

Dae Han New Pharm                         30.00%

Dosbol Zholdybayev                         13.61%

Cody Star Investment                          2.15%


Total                                                   100.00%


Further improvements in transparency


Under the terms of the Merger Agreement Kuat Oraziman and Dosbol Zholdybayev will, in due course, set up their own structures to individually hold their interests in Baverstock, increasing the transparency of the Caspian Sunrise share register.


Resultant shareholdings in the Company (based on shares held by Baverstock being allocated to the individual Quota-holders)


Kuat Oraziman #                   763,706,615              45.74%


Dae Han New Pharm            224,830,963              13.47%


Kairat Satylganov                  205,428,656              12.30%


Dosbol Zholdybayev             101,998,314              6.11%


#  includes direct holdings, holdings of Vertom and his effective portion of Baverstock


Orderly Markets agreements


Baverstock and Vertom have agreed to enter into an orderly market agreement restricting any disposal of the Consideration Shares and Conversion Shares for a six-month period from the completion of the Merger. Transfers of Consideration Shares to the underlying Baverstock Quota holders (or their nominees) are exempt provided the Baverstock Quota holder enters into an orderly market agreement in like terms.



Total Voting Rights


Following the issue of the Merger Shares and the Vertom Loan Capitalisation shares the total number of Ordinary Shares in issue following is 1,669,673,820.


Caspian Sunrise has no shares in treasury, therefore (subject to any further share issuance prior to Admission) this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.



Clive Carver, Chairman of Caspian Sunrise commented:


„The merger brings 99% of our principal asset BNG under the Caspian Sunrise Group’s direct control. We are now free to develop the asset at a pace to suit ourselves.”





Caspian Sunrise plc                                                                  +7 727 375 0202

Clive Carver

Executive Chairman



WH Ireland, Nominated Adviser & Broker                     +44 (0) 207 220 1666

James Joyce

James Bavister


Abchurch                                                                               +44 (0) 207 398 7700

Tim Thompson / Rebecca Clube
















Rutter Offers Advice for Migrating to Office 365

ANDOVER, Mass., June 1, 2017 /PRNewswire/ — Rutter Networking Technologies, a leading information technology solutions provider in New England, today announced it is publishing a guide to help small- and medium-sized businesses safely migrate their data to the cloud-based Microsoft Office 365. The e-book, Office 365 Migration for SMBs: Overcoming the Security Obstacle, is available for free download at https://www.rutter-net.com/office-365-migration-for-smbs.

Small- and medium-sized businesses (SMBs) may consider moving to Microsoft Office 365 for any number of reasons. However, some organizations find out—often too late—that not enough due diligence went into the migration, particularly in regard to security, thus resulting in serious issues that could have been avoided. Fortunately, Office 365 provides safeguards and standards to protect SMBs, which simply need to plan migrations the right way. Rutter’s new e-book offers strategies for implementing a successful and secure migration. Among the guide’s features:

  • Challenges that SMBs face when attempting to migrate to Office 365
  • Five common concerns regarding the cloud and how to overcome them

„Office 365 has clearly evolved over the years,” says Steve Brown, Partner and Senior Consultant for Rutter Networking Technologies. „Despite the solution extending its reach into the cloud and to mobile devices, your data can remain secure wherever it is stored. Our new guide offers actionable advice toward making a migration as smooth and safe as possible.”

To learn more about this e-book or Rutter’s services, visit www.rutter-net.com.

About Rutter Networking Technologies
Rutter Networking Technologies, Inc., is a leading end-to-end technology solutions provider in the Northeast. Rutter’s expertise and services include design/development; virtualization; migrations; project management; WAN services and remote network management; phone support; and staff augmentation. For more information, visit https://www.rutter-net.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rutter-offers-advice-for-migrating-to-office-365-300466063.html

SOURCE Rutter Networking Technologies

Related Links


Anti-Obesity Drugs Market Set to Witness Y-o-Y Growth by 2022

According to World Health Organization (WHO), obesity refers a disorder of accumulation of excessive fat that can impair health. Body Mass Index (BMI) is an index of weight for height, which is a measure for classifying obesity and overweight. According to WHO, BMI greater than or equal to 30 is consider as an Obese. Anti-obesity drugs refers the drugs that reduces or control the body weight by either reducing the appetite or increasing the absorption of calories. The fundamental treatment for obesity is to control over unhealthy diet, and regular exercise, as although anti-obesity drugs are available in the market, their usefulness is restricted to maintain weight rather than cure. Obesity is a risk factor for development of several chronic diseases such as coronary heart diseases, hypertension, metabolic disorders such as diabetes, and others. Hence, need to control by proper medication, diet, and exercise. Bariatric surgery is an also option for weight loss for BMI more than 40. However, lifelong changes in eating and exercise habits are necessary after surgery.

To get the view of full report @ http://www.persistencemarketresearch.com/market-research/antiobesity-drugs-market.asp

Global anti-obesity drugs market segmented by approved drugs: buproprion and naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), and liraglutide (Saxenda). Geographically, global anti-obesity drugs market segmented into North America, Europe, Asia Pacific, Latin America, and rest of the World. Presently, North America holds largest share of the market due to increasing obese population. For instance, according to Centers for Disease Control and Prevention (CDC), more than one third of U.S. population is obese in 2014. However, Asia Pacific expected to grow at highest rate due to increasing demand of drugs, and awareness regarding risk associated with obesity. Additionally, sedentary lifestyle, and unhealthy diet would expect to increase the number of obese people during forecast period.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/8884

Increase in incidence of obesity is majorly due to lack of physical activity, lack of sleep, and high calorie diet. Additionally, family history, and consumption of certain medicines such as antidepressant, diabetes agent also play a major role in obesity. For instance, according to World Health Organization (WHO), about 13% of world’s population were obese in 2014. Additionally, according to WHO, in emerging countries the rate of increase of childhood obesity has been more than 30% higher than that of developed countries. However, several side effects such as risk of psychiatric disorder, non-fatal myocardial infraction, or stroke could affect the market negatively albeit. Hence, development of medicines with lesser side effects with chronic use, and increasing focus on developing countries market can help to boost the market.

Recently, in September 2014 U.S. FDA approved Contrave, an extended release tablet for chronic weight management. Contrave is a combination of two already FDA-approved drugs, naltrexone and bupropion, and distributed by Takeda Pharmaceuticals America Inc. However, the drug is acting by very different mechanism of mesolimbic pathway. Hence, approval of such a drugs in the market could expect to surge the market growth.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/8884

Key players in the global anti-obesity market are Arena Pharmaceuticals, Bristol-Myers Squibb, Alizyme, Boehringer Ingelheim GmbH, Eisai Company, Ltd., F. Hoffmann-La Roche, GlaxoSmithKline plc, Bayer AG, Inc., Novo Nordisk, and Norgine Pharmaceuticals Ltd. Additionally, some other company includes Orexigen Therapeutics, Pfizer, Inc., Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Inc., and Zafgen.


About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Glance Pay Signs The Donnelly Group, a Dominant Hospitality Chain With 20 Locations in Vancouver and Toronto

VANCOUVER, British Columbia, June 1, 2017 /PRNewswire/ —

Glance Technologies Inc. (CSE: GET.CN) (OTCQB: GLNNF) (CSE: GET.WT), (FKT: GJT) is pleased to announce that Glance Pay, its mobile payment solution for merchants, has signed with one of Canada’s leading hospitality companies, The Donnelly Group. The Donnelly Group is an award-winning hospitality company, operating in both Vancouver and Toronto.

„The Donnelly Group understands what instills our competitive advantages and mobile payments, well done, is simply a demand of the times. We are excited to partner with Glance Pay and provide a mobile payment solution,” says Reid Ogdon, VP Operations, The Donnelly Group.

„When you look at popular culture today, The Donnelly Group sets the stage for innovation and a remarkable foresight to give guests an incredible experience at each of their venues. Leading the industry, with over eighteen years in business, Glance Pay is extremely proud to work with The Donnelly Group and speak to their core values of providing guests with a superior product, service, design and community with a collaborative approach. The Glance Pay solution aligns with these important ideals,” says Desmond Griffin, CEO, Glance.

About The Donnelly Group 

The Donnelly Group is an award winning and diversified hospitality company, operating in both Vancouver and Toronto, with continued expansion plans to grow in the coming months. The Donnelly Group establishments include Vancouver’s Cinema Public House, The Lamplighter Public House, Library Square Public House, Tavern, The Bimini Public House, The Blackbird Public House, The Butcher & Bullock, The New Oxford, The Three Brits, The Railway Stage & Beer Cafe, Clough Club, Granville Room, Royal Dinette and six Barber & Co locations, along with Belfast Love and Gift Shop in Toronto. The ethos of the company is to inspire modern pub culture – be true to yourself and your neighbourhood; the people will follow.

About Glance Technologies Inc. 

Glance Technologies owns and operates Glance Pay, a streamlined payment system that revolutionizes how smartphone users choose where to dine, order food & drink, settle bills, access digital receipts, earn great rewards, & interact with merchants. Glance is building a valuable network of merchants and consumers, and offers targeted in-app marketing, social media marketing, customer feedback, in-merchant messaging and custom rewards programs. The Glance Pay mobile payment system consists of proprietary technology, which includes user apps available for free downloads in IOS (Apple) and Android formats, a merchant manager app, large scale technology hosting environment with sophisticated anti-fraud technology and lightning fast payment processing.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statements 

This press release contains forward-looking information or forward-looking statements (collectively „forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is typically identified by words such as: „believe”, „expect”, „anticipate”, „intend”, „estimate”, „potentially” and similar expressions, or are those, which, by their nature, refer to future events. Glance cautions investors that any forward-looking information provided by Glance is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors. The reader is referred to Glances public filings for a more complete discussion of such risk factors and their potential effects which may be accessed through the Glance’s profile on SEDAR at www.sedar.com.

For more information about Glance, please go to Glance Technologies website

For more information, contact:
Christina Rao
Vice President, Investor Relations

SOURCE Glance Technologies Inc.